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Abstract
Background: Colorectal cancer is generally diagnosed following a symptomatic presentation to
primary care. Although the presenting features of the cancer are well described, the risks they
convey are less well known. This study aimed to quantify the risk of cancer for different symptoms,
across age groups and in both sexes.
Methods: This was a case-control study using pre-existing records in a large electronic primary
care database. Cases were patients aged 30 years or older with a diagnosis of colorectal cancer
between January 2001 and July 2006, matched to seven controls by age, sex and practice. All
features of colorectal cancer recorded in the 2 years before diagnosis were identified. Features
independently associated with cancer were identified using multivariable conditional logistic
regression, and their risk of cancer quantified.
Results: We identified 5477 cases, with 38,314 age, sex and practice-matched controls. Six
symptoms and two abnormal investigations (anaemia and microcytosis) were independently
associated with colorectal cancer. The positive predictive values of symptoms were: rectal
bleeding, positive predictive value for a male aged ≥ 80 years 4.5% (95% confidence interval 3.5,
5.9); change in bowel habit 3.9% (2.8, 5.5); weight loss 0.8% (0.5, 1.3); abdominal pain 1.2% (1.0,
1.4); diarrhoea 1.2% (1.0, 1.5) and constipation 0.7% (0.6, 0.8). Positive predictive values were
lower in females and younger patients. Only 27% of patients had reported either of the two higher
risk symptoms.
Conclusion: Most symptomatic colorectal cancers present with only a low-risk symptom. There
is a need to find a method of identifying those at highest risk of cancer from the large number
presenting with such symptoms.
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Over 35,000 colorectal cancers were diagnosed in England
in 2004 [1]. Survival in the UK is worse than in other
European countries and the US, partly because of later
presentation in the UK [2]. Delays in presentation to med-
ical care and diagnosis have been observed in several stud-
ies [3].
Early diagnosis may reduce mortality. The relative risk of
death from colorectal cancer is between 0.67 and 0.85 fol-
lowing faecal occult blood screening [4]. A large UK pro-
spective study of screening in half a million patients aged
50 to 69 years found 2% to be faecal occult blood (FOB)
positive, of whom 11% had colorectal cancer [5]. In 2006,
a UK national screening programme was introduced using
FOBs in people aged 60 to 69 years [6]. However, only
around a quarter of colorectal cancers are likely to be
detected in such a screening programme, because most
become symptomatic after this age, the sensitivity of the
test is only 60%, and almost half of eligible patients
decline screening [5,7]. Thus, most colorectal cancers will
continue to present with symptoms [8,9].
General practitioners (GPs) gain relatively little experi-
ence in the diagnosis of colorectal cancer because the inci-
dence is about one per GP per year, and only a proportion
of these are diagnosed in primary care [10]. In addition,
the relevant symptoms occur frequently in association
with benign conditions, which are also much more com-
mon. At least half of colorectal cancers only manifest low-
risk symptoms such as constipation or abdominal pain,
and there is no intermediate test to identify those particu-
larly likely to harbour cancer (unlike, for example, a chest
X-ray in possible lung cancer). Moreover, the main diag-
nostic test for suspected colorectal cancer is colonoscopy,
with a small but important complication rate.
The UK Referral Guidelines for Suspected Cancer [11],
which were updated in 2005, have a weak evidence base,
concentrate on typical presentations of cancer and may
even delay diagnosis in patients with atypical presenta-
tions [12]. Since publication of these guidelines, several
studies have reported risk estimates for the common
symptoms of colorectal cancer when presented to primary
care. Rectal bleeding studies reported positive predictive
values (PPVs) ranging from 2% to 6% [13-16]. Other
studies have examined change in bowel habit [14], anae-
mia [14,17], abdominal pain and loss of weight [15].
However, few studies have examined the effect of age or
sex. One calculated a steep increase in PPVs for rectal
bleeding and change in bowel habit with age, in parallel
with the increasing incidence of colorectal cancer [14].
Others showed a smaller rise [15] or almost none [18].
Males had higher PPVs for most clinical features, reflect-
ing the higher incidence in men. Differences with age and
sex are important; current guidance for referral ignores age
(other than setting a minimum age of 60 years for referral
with rectal bleeding or motility symptoms, and 40 years
when both are present) and sex (apart from a lower
threshold haemoglobin value for women). Most other
countries have no specific guidance for identification of
symptomatic colorectal cancer, although screening is rec-
ommended generally from the age of 50. We therefore
studied the symptoms of colorectal cancer in a large elec-
tronic dataset to calculate risk estimates in narrow age
bands and in both sexes.
Methods
Data were provided by The Health Improvement Network
(THIN), a database of electronic medical records
uploaded from general practices using the VISION com-
puter system. It is an offshoot of the General Practice
Research Database (GPRD), restricted to practices within
the GPRD using that specific computer technology. The
records contain patient characteristics, all prescriptions,
consultations, diagnoses and primary care investigations.
There are currently 2.2 million active patients in over 300
practices: 4.7 million patients when historical data are
included. The THIN database is subject to frequent inter-
nal quality checks, with any practices failing to maintain
adequate quality standards removed from the database.
Identification of cases and controls
Cases were patients aged 30 years or older with a diagno-
sis of colorectal cancer between January 2001 and July
2006 and at least 2 years of full electronic records before
diagnosis. Up to seven controls per case were selected (the
maximum allowed within THIN regulations), using a
computerised random number sequence. Controls were
matched for practice, sex and age, but had not had color-
ectal cancer: they also had at least 2 years of records before
the index date (the date of diagnosis of their matched
case). The full date of birth was unavailable to protect
anonymisation; however, the year of birth was available.
Where possible, controls were matched to the same year
of birth in years as cases; if no controls in this year were
available, they were matched to within 1 year, then 2 years
and so on up to a maximum of 5 years. THIN staff identi-
fied and provided complete records for all cases and con-
trols.
Definition of variables
From a review of the literature, 23 candidate variables
(features) were identified, either a symptom, or an abnor-
mal primary care investigation, or a predisposing risk
marker such as obesity. We also identified codes for irrita-
ble bowel syndrome as a potential misdiagnosis. For
some symptoms we were also able to take advantage of
the availability of data on related prescriptions, for exam-Page 2 of 9
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obtained as possible surrogates for the relevant symp-
toms, and similarly antispasmodic drugs for irritable
bowel syndrome. Features were designated as new if there
were no similar symptoms or prescriptions observed pre-
viously in the 2 years before the index date. Haemoglobin
values were categorised into 1 g/dl bands, and microcyto-
sis defined as a mean red cell volume ≤ 80 fl. Weight loss
was calculated from the change between the last recorded
weight and the highest weight in the previous 2 years, sep-
arated into two categories: ≥ 10% weight loss or 5% to
10% weight loss. Patients were assigned to their maxi-
mum weight loss category. Obesity was defined as a body
mass index > 30 kg/m2 within 2 years of the index date.
Diabetes was considered to be present if it had ever been
diagnosed.
Analysis: identification of variables independently 
associated with cancer
The main method of analysis was conditional logistic
regression. For the variables that also had prescriptions as
surrogates, preliminary analyses compared the odds ratio
for a prescription without a record of the feature with the
odds ratio for the feature itself. As these were similar for
all three of this type of variable, constipation, diarrhoea
and irritable bowel syndrome, the relevant pairs of varia-
bles were merged.
All variables with a univariable association with cancer
significant with a P value < 0.1 were entered into a staged
multivariable analysis. The first stage of the multivariable
analysis grouped clinically related variables together.
These were: intestinal motility features (constipation,
diarrhoea, change in bowel habit and flatulence); pain
features (irritable bowel syndrome, or prescription of an
antispasmodic and abdominal pain); bleeding features
(rectal bleeding, anaemia and microcytosis); systemic fea-
tures (weight loss and thrombo-embolism); obesity fea-
tures (diabetes and obesity). Only variables with a P value
< 0.05 within their group were considered for the final
model.
Analysis: estimation of PPVs
Age was stratified into four bands: 30 to 59 years (there
were too few cancers in this band for meaningful sub-divi-
sion) and 10-year bands thereafter, up to 80+ years. For
each age/sex/feature combination we created a 2 × 2 table
and calculated the positive likelihood ratio and its 95%
confidence intervals. We used Bayes' theorem (posterior
odds = prior odds × likelihood ratio) to estimate PPVs
[19]. The prior odds were derived from national incidence
rates stratified by age and sex for 2003 (the middle year of
our cohort), in that an annual incidence of, for example,
5 per 1000, is the equivalent of 199 to 1 odds against hav-
ing cancer diagnosed in the next year [20]. For males, the
annual incidence rates used were: aged 30 to 59 years,
0.026%; 60 to 69 years, 0.19%; 70 to 79 years, 0.35% and
80+ years, 0.43%. Female rates for the same age groups
were: 0.02%, 0.11%, 0.21% and 0.27%.
With the 5000 cases available, there was > 99% power to
detect 5% having a particular feature, compared with 1%
amongst controls. Such a difference was viewed in
advance as being potentially clinically useful, and from a
previous primary care study was considered possible [15].
Ethical approval was obtained from the London Multicen-
tre Research Ethics Committee.
Results
THIN staff identified 5477 cases from 317 practices and
were able to match 38,314 controls, with only seven very
elderly cases having fewer than seven controls available.
36,925 (96.4%) controls were matched to the same year
of birth, and 1150 (3%) to the adjoining year, leaving
only 239 controls 2 to 5 years different in age. 2911
(53.1%) of the cases were male. The median (inter-quar-
tile range) age at diagnosis of cases was 72 years (63, 79),
with males slightly younger: male median 71 years (62,
78) and female 73 (63, 81): P < 0.001, Wilcoxon test. The
frequencies of each clinical feature are shown in Table 1.
Less than 2.5% of cases or controls had an abnormal rectal
examination (15 cases, 2 controls), abdominal masses (86
cases, 19 controls), a positive FOB (7 cases, 2 controls), or
thrombo-embolism (24 cases, 74 controls). These (rare)
variables were omitted from further analyses. The final
multivariable model is shown in Table 2. PPVs for the six
symptoms independently associated with cancer, strati-
fied by age and sex, are shown in Figures 1, 2 and 3, with
scales varying for the high, medium and low-risk symp-
toms, respectively.
Discussion
This large study shows eight clinical features presenting in
primary care to be independently associated with the sub-
sequent diagnosis of cancer. All were previously known,
but the precise risk they confer had not been quantified
with such precision, nor have they been clearly differenti-
ated across ages and sexes. In general, the PPVs rose with
age, particularly after the age of 60, and were higher in
males. However, the absolute risk was relatively low
(below 2%) for all ages and both sexes for constipation,
diarrhoea, abdominal pain and loss of weight. Only
change in bowel habit (a term that GPs use when the pat-
tern of constipation or diarrhoea is particularly suggestive
of colon cancer, or is accompanied by additional symp-
toms) and rectal bleeding had PPVs of 2% to 5% (and
these higher PPVs were largely seen in males).Page 3 of 9
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Table 1: Frequency of clinical features in cases and controls.
Cases
(N = 5477)
Controls
(N = 38,314)
Positive likelihood 
ratio (95% CI)
Clinical feature Number with this 
feature
Percentage with 
this feature
Number with this 
feature
Percentage with 
this feature
Symptoms
Constipation 1477 27.0 4051 10.6 2.6 (2.4 to 2.7)
Diarrhoea 988 18.0 2171 5.7 3.2 (3.0 to 3.4)
Change in bowel habit 615 11.2 375 1.0 5.5 (5.2 to 5.8)
Rectal bleeding 853 15.6 460 1.2 6.0 (5.7 to 6.3)
Weight loss
5.0–9.9% 210 3.8 852 2.2 1.6 (1.4 to 1.8)
≥ 10% 351 6.4 678 1.8 2.9 (2.6 to 3.1)
Abdominal pain 1629 29.7 3121 8.1 3.5 (3.3 to 3.7)
Investigations
Haemoglobin < 12.0 
g/dl
1424 26.0 1803 4.7 4.4 (4.2 to 4.6)
Mean red cell volume 
< 80 fl
363 6.6 923 2.4 2.8 (2.4 to 3.1)
Diagnoses and risk 
factors
Irritable bowel 
syndrome
135 2.5 325 0.8 2.4 (2.1 to 2.8)
Diabetes 626 11.4 3679 9.6 1.2 (1.1 to 1.3)
Obesity 510 9.3 3510 9.2 1.0 (0.93 to 1.1)
Note: the positive likelihood ratio is the likelihood of having a feature when one is a case, divided by the likelihood of having the feature when one 
is a control.
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Table 2: Independent associations between clinical features and colorectal cancer in the final multivariable conditional logistic 
regression model.
Clinical feature Odds ratio (confidence interval)
Symptoms
Rectal bleeding 20 (17 to 23)
Change in bowel habit 14 (12 to 17)
Abdominal pain 3.9 (3.6 to 4.3)
Diarrhoea 2.4 (2.1 to 2.7)
Constipation 2.1 (1.9 to 2.3)
Weight loss
5.0–9.9% 1.2 (0.99 to 1.5)
≥ 10% 2.5 (2.1 to 3.0)
Investigations
Haemoglobin (g/dl)
12.0–12.9 1.7 (1.5 to 1.9)
11.0–11.9 2.8 (2.4 to 3.2)
10.0–10.9 5.9 (4.8 to 7.2)
9.0–9.9 9.3 (7.1 to 12)
< 9.0 18 (14 to 25)
Mean red cell volume < 80 fl 6.5 (5.3 to 7.9)
Note: associations adjusted for each other; all features have P < 0.001.
BMC Medicine 2009, 7:17 http://www.biomedcentral.com/1741-7015/7/17Strengths and weaknesses
This is the largest primary care study to examine all color-
ectal cancer symptoms. Its size has allowed estimates of
PPVs for relatively small age bands in either sex, and with
reasonably narrow confidence intervals. Furthermore, the
THIN database is representative of the UK as a whole, so
our results should be generalisable. However, there are
weaknesses too. We could not confirm cancer diagnoses,
although it is unlikely that such an important diagnosis
would have been entered erroneously particularly often.
We also could not examine histology or staging, as these
are only rarely recorded on primary care systems. The
study relied upon good recording of symptoms. This
problem is not quite as important as it appears, as under-
recording of symptoms occurring proportionately in both
cases and controls would not alter the likelihood ratios.
Only if under-recording was especially prevalent in one
group would a bias arise. It is impossible to know whether
cases or controls would be more prone to under-record-
ing. However, the PPVs are very similar to those derived
from paper records [15] (these may of course also suffer
from differential recoding of symptoms) and to the two
previous studies using electronic records [13,14]. One fur-
ther limitation was the study design: by matching for age
and sex, we could not examine these directly. Even so, the
dataset was large enough to allow age-sex stratified analy-
ses and estimation of PPVs.
Comparison with previous literature
Only three papers have used primary care data to estimate
risks of colorectal cancer across the ages and between the
sexes, although none with the size or precision of this one.
The first examined GP records directly and showed an
approximate tripling of PPV for rectal bleeding for those
aged over 70 compared with those aged 40 to 69 years
[15]. Two studies using electronic primary care records
reported a rise in the PPV for rectal bleeding across 10-year
age bands. This was also seen in the study reported here.
There is much less previous literature for other symptoms:
one study gives similar figures for change in bowel habit
[14], and the other again showed an approximate tripling
of PPV for constipation, diarrhoea and abdominal pain
between patients aged 40 to 69 years and those aged over
70 [15].
Relevance of the findings
It is important to use primary care data to provide evi-
dence for primary care decisions such as when to refer for
investigation. Current referral guidelines essentially
ignore age (other than giving a minimum age for referral)
Positive predictive values (PPVs) for rectal bleeding and change in bowel habit by age and sexFigure 1
Positive predictive values (PPVs) for rectal bleeding and change in bowel habit by age and sex.
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globin for referral). As the incidence of cancer rises steeply
with age, being 16 times higher in the oldest male age
group and 13 times higher in the oldest female group
when compared with the youngest groups, PPVs could
have been expected to differ by as much. They do not, as
the likelihood ratios fell with age. This presumably reflects
the increasing prevalence of benign causes of colorectal
cancer symptoms with age.
Two groups of symptoms emerge from the results. The
highest PPVs are for rectal bleeding and change in bowel
habit. For men over 60 years, rectal bleeding PPVs ranged
from 2.4% to 4.5%; most would agree these figures are
high enough to warrant investigation. For women, the fig-
ures were lower, but still in the 2% to 3% range. Change
in bowel habit is less simple: GPs contributing to THIN
must have been using this term very differently from the
separate terms of constipation and diarrhoea, in that the
PPVs for change in bowel habit were considerably higher.
We cannot know what features led GPs to write change in
bowel habit in the notes in preference to the specific
motility symptoms, however, from our results it is clear
that they were identifying a riskier feature, and one that
warrants investigation.
In contrast, the PPVs for constipation, diarrhoea, abdom-
inal pain and loss of weight were all below 1.5%, confirm-
ing that they are low-risk symptoms, at any age and in
either sex. Indeed, this is the first study to show that the
risk of colorectal cancer increases with increasing weight
loss. This is no surprise (and is a testament to the quality
of THIN data). However, these four symptoms are not 'no-
risk' symptoms. This creates a problem for design of refer-
ral strategies. The high-risk symptoms of rectal bleeding
and change in bowel habit were only recorded in 15.6%
and 11.2% of cases, respectively. Even allowing for possi-
ble under-recording, it is highly likely that only a minority
of patients with colorectal cancer have a high-risk symp-
tom. The majority, with only a low-risk symptom, could
have their diagnosis expedited in a number of different
ways. Firstly, scoring systems such as the CAPER score may
refine the risk in such patients [21]. Secondly, it is possible
that biomarkers may be identified with adequate perform-
ance characteristics for use in such a population. Thirdly,
early work suggests that measurement of rectal DNA may
allow patients at high risk to be selected for investigation
[22]. Without one of these initiatives, or a combination of
them, patients with a low-risk symptom will continue to
be at risk of delayed diagnosis, and possible emergency
presentation [23].
PPVs for weight loss by age and sexFigure 2
PPVs for weight loss by age and sex.
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Our results generally support the National Institute for
Clinical Excellence referral guidance with respect to symp-
toms. This is in contrast to the guidance for anaemia, with
an unacceptably high PPV at the current threshold recom-
mended for referral [17]. The choice of 60 as a starting age
is supported by our findings. Colorectal cancer can occur
in younger age groups, but the risk with particular symp-
toms is very low [24]. Our findings strengthen the view
that rectal bleeding carries a high enough risk to warrant
investigation irrespective of other symptoms. Current
guidance requires persistence of bleeding for 6 weeks, or
accompanying diarrhoea [11]. In our opinion, these addi-
tional requirements are unnecessary given no study has
reported a risk below 2% for rectal bleeding per se. Even
so, there remains a major gap within current guidance: the
patient with the low-risk, but not no-risk, symptom. This
is important, and suggests a direction for research efforts
aimed at reducing mortality from colorectal cancer.
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